<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Virol</journal-id><journal-id journal-id-type="iso-abbrev">J. Med. Virol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1096-9071</journal-id><journal-id journal-id-type="publisher-id">JMV</journal-id><journal-title-group><journal-title>Journal of Medical Virology</journal-title></journal-title-group><issn pub-type="ppub">0146-6615</issn><issn pub-type="epub">1096-9071</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7436491</article-id><article-id pub-id-type="doi">10.1002/jmv.26408</article-id><article-id pub-id-type="publisher-id">JMV26408</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Convalescent plasma a clutch at straws in COVID&#x02010;19 management! A systematic review and meta&#x02010;analysis</article-title><alt-title alt-title-type="left-running-head">SARKAR <sc>et al.</sc></alt-title></title-group><contrib-group><contrib id="jmv26408-cr-0001" contrib-type="author"><name><surname>Sarkar</surname><given-names>Soumya</given-names><prefix>Dr.</prefix></name><degrees>M.D</degrees><xref ref-type="aff" rid="jmv26408-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jmv26408-cr-0002" contrib-type="author"><name><surname>Soni</surname><given-names>Kapil Dev</given-names><prefix>Dr.</prefix></name><degrees>M.D</degrees><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1214-4119</contrib-id><xref ref-type="aff" rid="jmv26408-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jmv26408-cr-0003" contrib-type="author" corresp="yes"><name><surname>Khanna</surname><given-names>Puneet</given-names><prefix>Dr.</prefix></name><degrees>M.D</degrees><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9243-9963</contrib-id><xref ref-type="aff" rid="jmv26408-aff-0001">
<sup>1</sup>
</xref><address><email>k.punit@yahoo.com</email></address></contrib></contrib-group><aff id="jmv26408-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Anaesthesia</named-content>
<institution>pain medicine &#x00026; Critical Care, AIIMS</institution>
<named-content content-type="country-part">New Delhi</named-content>
<country country="IN">India</country>
</aff><aff id="jmv26408-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Critical &#x00026; Intensive Care</named-content>
<institution>JPN Apex Trauma Centre, AIIMS</institution>
<named-content content-type="country-part">New Delhi</named-content>
<country country="IN">India</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence Dr.Puneet Khanna, Department of Anaesthesia, pain medicine &#x00026; Critical Care, AIIMS, Ansari Nagar, NewDelhi&#x02010;110029.<break/>
Email: <email>k.punit@yahoo.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>8</month><year>2020</year></pub-date><elocation-id>10.1002/jmv.26408</elocation-id><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Wiley Periodicals LLC <copyright-statement>--><copyright-statement content-type="article-copyright">This article is protected by copyright. All rights reserved.</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JMV-9999-na.pdf"/><abstract><title>Abstract</title><sec id="jmv26408-sec-0010"><title>Background</title><p>In absence of definitive therapy for coronavirus disease (COVID&#x02010;19), convalescent plasma therapy (CPT) may be a critical therapeutic option. This review was conducted to evaluate the impact of CPT in COVID&#x02010;19 patients based on the publications reported to date.</p></sec><sec id="jmv26408-sec-0020"><title>Methods</title><p>A robust screening of electronic databases was conducted up to 10<sup>th</sup> July 2020. The randomized controlled trials (RCTs), cohort studies, and case series with control group evaluating the effectiveness and safety of CPT in patients with COVID&#x02010;19 are included for the meta&#x02010;analyses.</p></sec><sec id="jmv26408-sec-0030"><title>Results</title><p>Our search retrieved seven studies, including two RCTs and five cohort studies, with a total of 5,444 patients. In patients with COVID&#x02010;19, the use of CPT reduces mortality [Odd's ratio (OR) 0.44, 95% CI 0.25 to 0.77], increases viral clearance [OR 11.29, 95% CI 4.9 to 25.9] and improves clinically [OR 2.06, 95% CI 0.8 to 4.9].However, the evidences are of low quality (mortality reduction, and viral clearance),and very low quality (clinical improvement).</p></sec><sec id="jmv26408-sec-0040"><title>Conclusions</title><p>CPT may be beneficial for reducing mortality, viral shedding. and improving clinical conditions in COVID&#x02010;19 patients. However, further randomized control trials (RCT) are required to substantiate the safety margin, initiation, optimal dosage, titre and duration of CPT.</p><p>This article is protected by copyright. All rights reserved.</p></sec></abstract><kwd-group><kwd id="jmv26408-kwd-0001">(COVID&#x02010;19): coronavirus disease</kwd><kwd id="jmv26408-kwd-0002">(CPT): convalescent plasma therapy</kwd><kwd id="jmv26408-kwd-0003">(SARS&#x02010;CoV&#x02010;2): severe acute respiratory syndrome coronavirus&#x02010;2</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><page-count count="25"/><word-count count="330"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>accepted-manuscript</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.7 mode:remove_FC converted:19.08.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="jmv26408-note-0001"><p>This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.26408</p></fn></fn-group></notes></front></article>